Mass Spectrometry System suits research/translational medicine studies.
Press Release Summary:
Offered with 96- and 384-well options, benchtop MassARRAY® Analyzer 4 can be used for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis, as well as high-throughput genotyping and SNP fine mapping applications. This MALDI-TOF mass spectrometry-based nucleic acid analysis platform can run tens to thousands of samples daily and analyze any combination of genetic markers and samples. Also included, analyzer control software reduces hands-on time.
Original Press Release:
Sequenom Introduces the MassARRAY Analyzer 4 System
Next-Generation Proprietary Platform Makes High-Performance Mass Spectrometry Available to Broad Market
SAN DIEGO -- Sequenom, Inc. (NASDAQ: SQNM) today announced the launch of its next-generation mass spectrometry system - the MassARRAY® Analyzer 4. This new high performance nucleic acid analysis platform has been designed to meet customer demand for a bench top instrument with greater flexibility across multiple applications, improved reliability and faster performance. With the capability for quantitative gene expression analysis, epigenetic nucleic acid methylation analysis as well as high-throughput genotyping and SNP fine mapping applications, the MassARRAY Analyzer 4 is designed to empower the basic and translational research community to advance findings from basic genetic and biomarker studies toward clinical utility in diagnosis, prognosis and monitoring of diseases.
The MassARRAY Analyzer 4 system will initially be offered to research-use-only (RUO) laboratories, and subject to FDA clearance will be released to CLIA-certified laboratories for the generation and implementation of laboratory-developed tests.
The new system has been configured to provide increased throughput, faster time-to-results, and the ability to cost-effectively run from tens to thousands of samples daily -- making this an ideal genetic analysis system for use in basic and translational research.
Benefits of the MassARRAY Analyzer 4 system include:
-- Shorter time-to-result with up to two times faster chip scan rate
-- Features that accommodate the needs of both low- and high-throughput laboratories with 96 and 384-well options
-- New easy-to-use Analyzer control software reduces hands-on time
-- Flexibility to analyze any combination of genetic markers and samples
-- Suitability for a variety of applications including genotyping, somatic mutations, and DNA methylation
-- Improved reliability that should result in less maintenance
"With the addition of the MassARRAY Analyzer 4 system, Sequenom now offers a faster, more robust instrument which builds upon our proven MassARRAY technology shown to produce high quality data," said Michael Monko, senior vice president, genetic analysis sales and marketing. "The launch of this cost-effective instrument should allow a wider range of labs and institutions to add the power of mass spectrometry-based applications to their research and translational medicine studies. Additionally, having a system built under design control will allow us to pursue our ultimate goal of registering the system and related tests for FDA approval."
For more information on the MassARRAY Analyzer 4, please visit http://www.massarrayanalyzer.com/.
About MassARRAY Technology
Sequenom's proprietary MassARRAY® system is a high performance, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based nucleic acid analysis platform that quantitatively measures genetic target material and its variations in a rapid, accurate, and cost efficient manner. Sequenom's MassARRAY system facilitates a number of nucleic acid analysis applications including SNP genotyping and allelotyping, somatic mutation analysis, CNV analysis, quantitative gene expression analysis, quantitative methylation marker analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control.
About Sequenom
Sequenom, Inc. (NASDAQ:SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery & clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at www.sequenom.com/ to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
Sequenom® and MassARRAY® are trademarks of Sequenom, Inc. All other trademarks and service marks are the property of their respective owners.
